Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine

John S. Oxford*, Ali A. Al-Jabri, Robert Lambkin, A. M. Palache, D. M. Fleming

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


We have investigated whether 'at risk' subjects who did not respond serologically during a pre-study vaccination with a commercial egg grown influenza sub-unit vaccine would respond to a subsequent vaccination with either a single dose of MDCK cell grown influenza vaccine or a standard egg grown influenza vaccine containing the same virus strains. We studied 48 non-responder subjects with a mean age 67.5, range: 34-82 years. In this non-responder group the increased immune response that was detected after boosting with an MDCK cell derived vaccine response was variable and relatively modest, except for the A/Texas strain in the vaccine. The proportion of subjects, with an HI titre of ≥40 (protective antibody titre) increased from 50 to 83% (A/Texas strain), from 13 to 25% (B/Harbin strain) and from 38 to 46% (A/Wuhan strain). In comparison a booster vaccination with egg-derived influenza vaccine resulted in an increase immune response with an HI antibody titre ≥40 for two of the three strains, namely from 17 to 58% for the B/Harbin strain and from 8 to 33% for the A/Wuhan strain.

Original languageEnglish
Pages (from-to)2743-2746
Number of pages4
Issue number21-22
Publication statusPublished - Jun 20 2003


  • Cell grown vaccine
  • Influenza vaccine seroconvert
  • MDCK
  • Non-responders

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine'. Together they form a unique fingerprint.

Cite this